Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: A brief history of time

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Rodriguez Roisin, Roberto ^a,b   Rabe, Klaus F ^c,d   Vestbo, Jørgen ^e,f   Vogelmeier, Claus ^g   Agustí, Alvar ^a,b,h,i  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF KIEL   (Germany)

^d Airway Research Centre North of the German Centre for Lung Research (DZL)   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

^g German Centre for Lung Research (DZL)   (Germany)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; EVIDENCE BASED PRACTICE; FORCED EXPIRATORY VOLUME; HEALTH PROMOTION; HISTORY; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLISHING; REVIEW; SECONDARY PREVENTION; SPIROMETRY; GLOBAL HEALTH; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PROCEDURES; PULMONOLOGY; SEVERITY OF ILLNESS INDEX; WORLD HEALTH ORGANIZATION;

GLOBAL HEALTH; HEALTH PROMOTION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL COOPERATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; SEVERITY OF ILLNESS INDEX; WORLD HEALTH ORGANIZATION;

EID: 85026236281     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00671-2017     Document Type: Review

References (33)

1. Pauwels R. Global initiative for chronic obstructive lung diseases (GOLD): Time to act. Eur Respir J 2001; 18: 901-902.
2. Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (2017 Report) 2017. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
3. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
5. Vestbo J, Hurd SS, Agustí A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
6. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive summary. Eur Respir J 2017; 49: 1700214.
7. Hurd S. The impact of COPD on lung health worldwide: Epidemiology and incidence. Chest 2000; 117: Suppl. 2, 1S-4S.
8. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997; 349: 1269-1276.
9. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997; 349: 1347-1352.
10. Bousquet J, Fabbri LM, O'Byrne P, et al. In memoriam Romain Pauwels. Eur Respir J 2005; 25: 585-586.
11. Roccella EJ. Giants in Chest Medicine: Claude Lenfant, MD. Chest 2017; 151: 11-13.
12. Rodriguez-Roisin R, Han MK, Vestbo J, et al. Chronic respiratory symptoms with normal spirometry. A reliable clinical entity? Am J Respir Crit Care Med 2017; 195: 17-22.
13. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2.
14. Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
15. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002; 121: Suppl. 5, 127S-130S.
16. Celli BR, MacNee W, Agusti AG, et al. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
17. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 2002; 166: 329-332.
18. Celli BR, Cote CG, Marin JM, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
19. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
20. Soler-Cataluña JJ, Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: How much real, how much fictitious?. COPD 2010; 7: 276-284.
21. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
22. Agusti A, Hurd S, Jones P, et al. Frequently asked questions (FAQs) about the GOLD 2011 assessment proposal of COPD. Eur Respir J 2013; 42: 1391-1401.
23. Agusti A. The path to personalized medicine in COPD. Thorax 2014; 69: 857-864.
24. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive summary. Am J Respir Crit Care Med 2017; 195: 557-582.
25. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive summary. Arch Bronconeumol 2017; 53: 128-149.
26. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive summary. Respirology 2017; 22: 575-601.
27. Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: A pooled analysis of individual patient data. Lancet Respir Med 2015; 3: 443-450.
28. Goossens LM, Leimer I, Metzdorf N, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: A post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med 2014; 14: 163.
29. Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 1819-1827.
30. Han MK, Mullerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: A prospective cohort study. Lancet Respir Med 2013; 1: 43-50.
31. Suissa S, Rossi A. Weaning from inhaled corticosteroids in COPD: The evidence. Eur Respir J 2015; 46: 1232-1235.
32. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294.
33. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390-398.